Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | MMP8 | P22894 | 7/20 | 0.52 |
| ▸ | MMP13 | P45452 | 6/20 | 0.52 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.51 |
| ▸ | MMP3 | P08254 | 1/20 | 0.51 |
| ▸ | MMP12 | P39900 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8180501 | 0.91 | MAPT (0.55) | PARP1TSHRMAOAMMP8MMP13 | |
| SCHEMBL14073306 | 0.85 | USP2 (0.59) | PARP1TSHRMAOAMMP8MMP13 | |
| SCHEMBL14073344 | 0.85 | TSHR (0.55) | PARP1TSHRMAOAMMP8MMP13 | |
| SCHEMBL8189957 | 0.83 | MMP13 (0.74) | PARP1TSHRMAOAMMP8MMP13 | |
| SCHEMBL14073152 | 0.82 | TSHR (0.59) | PARP1TSHRMAOAMMP8MMP13 | |
| SCHEMBL13344138 | 0.82 | MMP13 (0.66) | PARP1TSHRMAOAMMP8MMP13 | |
| SCHEMBL14073320 | 0.82 | TSHR (0.54) | PARP1TSHRMAOAMMP8MMP13 | |
| SCHEMBL14073312 | 0.80 | TSHR (0.59) | PARP1TSHRMAOAMMP8MMP13 | |
| SCHEMBL14073279 | 0.80 | HPGD (0.64) | PARP1TSHRMAOAMMP8MMP13 | |
| SCHEMBL14073299 | 0.80 | TSHR (0.58) | PARP1TSHRMAOAMMP8MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | NOLTE BERT | 2008-07-24 | — | — | US | disclosed |
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | NOLTE BERT | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | ADAM17, ADAM8, ADAM10 | PARP1 496/4885TSHR 4588/4885MAOA 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.